Navigation Links
BioConvergence® Presents Case Study on Temperature Controlled Pharmaceutical Products
Date:10/19/2013

Bloomington, Indiana (PRWEB) October 18, 2013

BioConvergence team members Désirée Valentine and Travis Hudson presented their newest case study (including outcomes of yielding a 99.7 percent excursion-free shipping rate) at the 11th Annual Cold Chain & Temperature Management Global Forum in Chicago, IL earlier this month.

The conference, led by IQPC, focused on shipping regulations, strategies, and trends within the life sciences industry, with special emphasis on maintaining product integrity through temperature management.

“There is plenty of evidence that suggests that a product’s temperature (and the associated fluctuations) can have profound impacts on a product’s stability, and therefore, its therapeutic effectiveness,” relates Valentine, Senior Supply Chain Manager at BioConvergence. “Because of this, BioConvergence is committed to keeping our clients’ products within appropriate temperature conditions while at our facility and throughout transit. This year, our team has implemented key changes that have resulted in improved metrics and additional value to clients. In presenting this data at IQPC, we hope that others will utilize this case study to realize similar results and promote improvements throughout the pharmaceutical supply chain.”

These improvements, as were discussed in Valentine and Hudson’s presentation, are as follows:

  •     Yielded a 99.7 percent excursion-free rate
  •     Decreased Average Days in Transit by over 1 day per shipment
  •     Reduced Days in Transit (50% reduction in “Delivery Past Qualification” time)
  •     Improved coordination, both internally and externally
  •     Established processes for continual improvement moving forward

When asked how BioConvergence achieved these results, Hudson, Associate Process Engineer at BioConvergence, responded, “We began by having a clear picture of the results we wanted to see: improvements to key performance indicators and partnerships, as well as reductions to excursion rates. Next, we began an in-depth analysis of our existing processes and flagged five specific root causes that were interfering with outcomes. After strategically addressing each of these items, we began to see improvements in our metrics. This process has become the standard at BioC in promoting continual improvements.”

In addition to presenting this case study, Valentine and Hudson also led a roundtable discussion during the conference entitled, “How to Create Value through Designing and Implementing a Shipping Lane Qualification for High Value Pharmaceutical Products.”

To learn more about the framework BioConvergence developed, download the full case study at http://www.bioc.us/iqpc.

About BioConvergence

BioConvergence is a contract service provider to the life sciences industry, offering outsourcing partnerships for formulation development, testing, production, and supply chain services. Headquartered in Bloomington, Indiana, BioC has over 50 employees with more than four centuries’ worth of combined experience in the pharmaceutical industry. BioC’s unique E-Transparency® System provides transparency and flexibility to its clients, while offering superior, quality-driven outsourcing services. For more information, visit http://www.bioc.us.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11245946.htm.


'/>"/>
Source: PRWeb
Copyright2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BioConvergence®, Contract Manufacturing Organization for the Life Sciences Industry, Announces New Board of Directors
2. CEO of BioConvergence® Receives Women Excel Bloomington Award for Outstanding Leadership and Service
3. BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment
4. BioConvergence® Launches New Blog Aimed at Exploring Best Practices of Pharmaceutical and Biotechnology Industries
5. BioConvergence® Celebrates Seventh Anniversary as a Life Sciences Contract Service Provider
6. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
7. FarHawk Marketing Services Represents IonBench™ and MS Noise™ at the Greater Boston Mass Spectrometry Discussion Group Corporate Night October 3rd
8. San Francisco Business Times Presents: Richmond! Your Home Front for Business
9. Quorum Review’s Mitchell Parrish Presents at Embracing Change: Clinical Research in the 21st Century
10. Bayer CropScience Presents on Bee Health and Stewardship at International Pollinator Conference
11. Clinovo Presents Its Paper ‘Cloud for Clinical Trials’ at Society for Clinical Data Management (SCDM) Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Minn. , Feb. 23, 2017  Imanis ... new product line of oncolytic vaccinia viruses for ... Corporation as part of Genelux,s proprietary, vaccinia virus-based ... are excited to enter into a partnership with ... selected oncolytic vaccinia viruses for use in research," ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can ... adiponectin, uric acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect ... SalivaLab , the relationship between insulin and other relevant biomarkers can be extensively ...
(Date:2/23/2017)... and SAN FRANCISCO , Feb. 23, ... medicine company, and Beyond Type 1, a not-for-profit advocacy ... diabetes, today announced a grant from Beyond Type 1 ... for type 1 and other insulin-requiring diabetes.  ... developing innovative stem cell-derived cell replacement therapies with a ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , a leader in Atomic ... all SPIE attendees and Park customers on Feb. 27, 2017 from 12-2pm ... Jose Convention Center. The luncheon will feature a talk on Automated AFM for ...
Breaking Biology Technology:
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/25/2017)... Jan. 25, 2017 The Elements of Enterprise ... lifecycle is comprised of a comprehensive set of ... of maintaining digital identities and providing a secured ... There are significant number of programs opted by ... time by optimizing processes and changing policies. However, ...
Breaking Biology News(10 mins):